Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Ochi A"'
Autor:
Shoichi Kuyama, Kenichiro Kudo, Toshio Kubo, Nobukazu Fujimoto, Akihiro Bessho, Yoshinobu Maeda, Naoyuki Nogami, Makoto Sakugawa, Katsuyuki Hotta, Kadoaki Ohashi, Takashi Ninomiya, Katsuyuki Kiura, Daijiro Harada, Keisuke Aoe, Eiki Ichihara, Daisuke Minami, Keisuke Sugimoto, Nobuaki Ochi, Toshiyuki Kozuki, Nagio Takigawa
Publikováno v:
Japanese Journal of Clinical Oncology. 51:1269-1276
Background In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer
Autor:
Naofumi Hara, Takuo Shibayama, Yoshinobu Maeda, Katsuyuki Kiura, Shingo Harita, Daizo Kishino, Daijiro Harada, Eiki Ichihara, Nobuaki Ochi, Katsuyuki Hotta, Koji Inoue, Shinobu Hosokawa, Nagio Takigawa, Naohiro Oda
Publikováno v:
European Journal of Cancer. 149:73-81
Background Immune checkpoint inhibitors (ICIs) are essential for treatment of various malignancies, including non–small-cell lung cancer (NSCLC). Recently, several studies have shown that the gut microbiome plays an important role in ICI treatment
Autor:
Junko Watanabe, Issei Sumiyoshi, Naoko Shimada, Shin-ichiro Iwakami, Kotaro Kadoya, Yusuke Ochi, Kazuhisa Takahashi, Rina Shibayama, Shinsaku Togo, Haruhi Takagi, Hiroaki Motomura, Takahiro Okabe, Moe Iwai, Yuichi Fujimoto, Mizuki Haraguchi
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Journal of Translational Medicine
Journal of Translational Medicine
Background Regimens combining pemetrexed (PEM) and immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are widely used for the treatment of advanced non-squamous non-small-cell lung cancer
Autor:
Daisuke Minami, Hiromi Watanabe, Katsuyuki Hotta, Masahiro Tabata, Kenichiro Kudo, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Etsuko Murakami, Kammei Rai, Nobuaki Ochi, Kiichiro Ninomiya, Katsuyuki Kiura, Kadoaki Ohashi, Daijiro Harada, Yoshinobu Maeda, Masayuki Yasugi, Keiichi Fujiwara
Publikováno v:
Japanese Journal of Clinical Oncology. 50:1447-1453
Objectives Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged
Autor:
Michael McCleod, Alona Zer, Steven L. McCune, Marcin Kowanetz, Henry Jacob Conter, Hans-Georg Kopp, Tarek Mekhail, Niels Reinmuth, W. Lin, Ahad Sadiq, Lijia Wang, Alan Sandler, Maen A. Hussein, Federico Cappuzzo, V. Archer, Achim Rittmeyer, Davey B. Daniel, Howard Jack West, Tania Ochi Lohmann, Alessandro Morabito
Publikováno v:
The Lancet Oncology. 20:924-937
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with ch
Autor:
Katsuyuki Kiura, Keisuke Sugimoto, Shoichi Kuyama, Isao Oze, Toshiyuki Kozuki, Masahiro Kodani, Seigo Miyoshi, Takuo Shibayama, Nobuhisa Ishikawa, Yutaka Ueda, Masayuki Yasugi, Tadashi Maeda, Tomoya Ishii, Tetsuya Kubota, Yoshihiro Amano, Nobuaki Ochi, Kazuhiko Watanabe, Koji Inoue, Toshihide Yokoyama, Kazunori Fujitaka, Takashi Ninomiya, Toshio Kubo, Akihiro Bessho, Katsuyuki Hotta
Publikováno v:
Clinical Lung Cancer. 20:134-138
Afatinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has demonstrated a significant survival benefit over platinum-based chemotherapy in a first-line setting in advanced non–small-cell lung cancer (
Autor:
Yoshinobu Maeda, Naofumi Hara, Naohiro Oda, Eiki Ichihara, Koji Inoue, Shinobu Hosokawa, Daizo Kishino, Katsuyuki Hotta, Nagio Takigawa, Katsuyuki Kiura, Daijiro Harada, Takuo Shibayama, Shingo Harita, Nobuaki Ochi
Publikováno v:
European Journal of Cancer. 157:523-524
Publikováno v:
Translational Lung Cancer Research. 7:S352-S355
MET dysregulation occurs in up to 26% of non-small-cell lung cancers (NSCLCs) after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment. Capmatinib (INC280) is a potent and selective MET inhibitor with preclinical activi
Autor:
Hirohisa Ichikawa, Nagio Takigawa, Toshihide Yokoyama, Shingo Harita, Naohiro Oda, Yoshinobu Maeda, Toshi Murakami, Nobuaki Ochi, Eiki Ichihara, Kiichiro Ninomiya, Kastuyuki Hotta, Kenichi Chikamori, Katsuyuki Kiura, Daisuke Minami
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:1031-1038
The aim of this study was to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration using afatinib in patients with non-small-cell lung cancer (NSCLC) with a sensitive non-T790M EGFR mutation
Autor:
Tomoko Yamagishi, Hidekazu Nakanishi, Nozomu Nakagawa, Nobuaki Ochi, Shigeki Umemura, Nagio Takigawa, Yasunari Nagasaki, Tatsuyuki Kawahara, Hiromichi Yamane, Yoshihiro Honda
Publikováno v:
Japanese Journal of Clinical Oncology. 48:995-1000
Introduction Since June 2005, the University Hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR) has been an International Committee of Medical Journal Editors (ICMJE)-approved clinical trial registry in Japan. The number of clini